

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NUMBERMTH-0003-P2_ SERIAL NUMBE							
	ALMIC PREPARATION						
CONTAINING GLYCOMACROPEPTIDE EXAMINER	ART UNIT						
<ol> <li>Applicant submits herewith a copy of (a) attached form PTO-1449, which lis submitted for consideration by the Office; (b) a legible copy of each document</li> </ol>	ts all patents, publications, applications, or other information required by 37 C.F.R. §1.98(b)(2).						
<ol> <li>Applicant herein apprises the Patent Office of references cited in a parent U.S. application filing date under 35 U.S.C. §120. The Serial Number of the parent application filed and entitled and entitled The publications cited therein are listed on attached Form PTO-1449. In according to the publications cited therein are listed on attached form PTO-1449.</li> </ol>	is U.S. Application						
are not required.   Additional parent patent applications are listed on an att	ached sheet.						
<ul> <li>In accordance with 37 C.F.R. §1.98(a)(3), Applicant hereby certifies that for each of the company of a translation of one or more non-English document, or portion A concise explanation is (check at least one box below):</li> </ul>	thereof, is provided herewith;						
provided in the accompanying foreign or international search report;	incorporated into the specification; and/or uprovided nerewith.						
<ol> <li>\$1.97(b)(1), (b)(2) – WITHIN 3 MONTHS OF FILING OR ENTRY IN NATIONA</li> <li>Since this Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an i §1.97(e) is required.</li> </ol>	f the filing date of the subject application or within three months						
<ul> <li>37 C.F.R. 1.97(b)(3), (b)(4) – PRIOR TO MAILING OF FIRST OFFICE ACTION OR FIRST AS Since this Information Disclosure Statement is being filed before the mailing do of a first Office action after the filing of a request for continued examination u §1.97(e) is required.</li> </ul>	ate of the first Office Action on the merits, or before the mailing						
37 C.F. R. §1.97(c) – AFTER FIRST ACTION, BEFORE FINAL ACTION OR ALLOWA	NCE						
<ul> <li>Since this Information Disclosure Statement is being filed outside of the period of a Final Rejection or Notice of Allowance, this submission is being accompa</li> <li>the fee required under 37 C.F.R. §1.97(c)(2) and specified in 37 C.F.R. §1.97(e) (Box 8 or 9 must be che</li> </ul>	provided for in 37 C.F.R. §1.97(b), but before the mailing date nied by (one of the following boxes must be checked): §1.17(p).						
<ul> <li>37 C.F.R. §1.97(d) – AFTER FINAL REJECTION OR ALLOWANCE</li> <li>7. Since this Information Disclosure Statement is being filed after the period specified and is accompanied by both the statement specified in 37 C.F.R. §1.97(e) be checked.)</li> </ul>	fied in 37 C.F.R. §1.97(c), but on or before payment of the issue and the fee set forth in 37 C.F.R. §1.17(p). (Box 8 or 9 must						
Statement was first cited in any communication from a foreign patent office in a c	In accordance with 37 C.F.R. §1.97(e)(1), Applicant's attorney certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.   The foreign or international search report(s) is/are enclosed.						
In accordance with 37 C.F.R. §1.97(e)(2), Applicant's attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of the information disclosure statement.							
10. In the event the Commissioner of Patents deems that any additional fee is required under 37 C.F.R. §§ 1.16 or 1.17 in connection with this application, Applicant's attorneys authorize that such fee be charged to Deposit Account No. 06-1130.							
11. Consideration of this Information Disclosure Statement is respectfully requested.							
Name: Daniel F. Drexler	Registration Number 47,535						
Signature V	Date 11-30-2005						
CERTIFICATE OF MAILING OR TRANSMISSION: I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or [ ] facsimile							
transmitted to the Patent and Trademark Office to Facsimile No on the date shown below.  Name Jennifer Lepage							
0/4 400/	Data 12 - 15						
Signature	Date 12-1-05						

•-	•			Docket Number (Optional) MTH-0003-P2		Application Number 10/813,998			
(	INFO	RMATION DISCLOSUR	. / \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		Applicant(s) EDWARD J. ELLIS	E TETE AT.			
		(Use several sheets if neces.	sary)	Tr.	Filing Date	<del></del>	Group Art Unit		
			DEC	复	03/30/04				
			A STORY	005 <sub>U.S.</sub> PAT	ENT DOCUMENTS			1	
EXAMINER INITIAL	REF	DOCUMENT NUMBER	& ADAJE MARY	Str.C.	NAME	CLASS	SUBCLASS		DATE OPRIATE
		5,578,586	11/26/96	Glonek	, et al.				
		5,371,108	12/06/94	Korb, e	t al.				
		5,294,607	03/15/94	Glonek	, et al.				
	5,278,151 01/11/94		Korb, e	t al.					
		4,914,088	04/03/90	Glonek	, et al.				
		4,818,537	04/04/89	Guo					
		4,804,539	02/14/89	Guo, et	al.				
		5,460,834	10/24/95	Bhagat					
		6,180,093	01/30/01	De, et a	l.				
		5,075,104	12/24/91	Gressel	, et al.				
		5,209,927	05/11/93	Gressel	, et al.				
				FOREIG	N PATENT DOCUMENTS	5			
	REF	DOCUMENT NUMBER	DATE	COUNTRY CLASS		CLASS	SUBCLASS	Translation	
								YES	NO
					<del>- , , , , , , , , , , , , , , , , , </del>				
							·		
				OTHER	DOCUMENTS (Including	ig Author, Title, I	Date, Pertinent Pa	ges, Etc.)	
		Stuart Patton, et al.; "	The Epithelial M	ucin, MUC	I, of Milk, Mammary Gl	and and Other	Tissue"; Bioche	mica et B	iophysica
		Acta 1241 (1995) page	S 4U/-424						
		L.T. Pallesen, et al.; "	Purification of MI	UC1 from E	Bovine Milk-Fat Globule 598; American Diary Sc	s and Characte	rization of a Co	rrespondi	ng
		Full-Length cDNA Clo	one"; J. Dairy Sci	. 84:2591-2	598; American Diary Sc	ience Association	on 2001		
EXAMINER				DATE CONSIDERED					
					<u> </u>				
		al if citation considered, whether clude copy of this form with nex			ce with MPEP Section 609	; Draw line throi	ugh citation if not	in conform	ance and

Form PTO-A820

OF 3

## Docket Number (Optional) Application Number INFORMATION DISCLOSURE COATION 425 (Use several sheets if necessary) MTH-0003-P2 10/813,998 Applicant(s) DEC 0 5 2005 EDWARD J. ELLIS, ET AL. Filing Date Group Art Unit 03/30/04

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	U.S. PATENT DOCUMENTS  NAME	CLASS	SUBCLASS	FILING	
EMILLE		5,225,196	07/06/93	Robinson		<del>                                     </del>	IF APPRO	OPRIATE_
		4,983,392	01/08/91	Robinson				
		4,615,697	10/07/86	Robinson				
		5,403,841	04/04/95	Lang, et al.				
		6,056,950	05/02/00	Saettone, et al.				
		4,438,100	03/20/84	Balslev, et al.				
		6,281,192	08/28/01	Leahy, et al.				
	0	6,429,194	08/06/02	Leahy, et al.		*		
		4,615,697	10/07/86	Robinson				
	5,188,826		02/23/93	Chandrasekaran, et al.				
2002/0045582		04/18/02	4/18/02 Margolin, et al.					
				FOREIGN PATENT DOCUMENTS				
	REF	DOCUMENT NUMBER	DATE	DATE COUNTRY		SUBCLASS	Translation	
						<del> </del>	YES	NO
			-					
	•					<u> </u>		<u> </u>
		I Yudawadi anal Caanah T	onest DCT/IC	OTHER DOCUMENTS (Including) 02/31657; 03 March 2003	Author, Title, D	ate, Pertinent Pa	ges, Etc.)	
		International Search F	report, r C 1/030	72/31037; 03 March 2003				

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: I	nitial if	citation considered, whether or not citation is in conforma	nce with MPEP Section 609; Draw line th	arough citation if not in conformance and		
EXAMINER	L		DATE CONSIDERED			
			<del> </del>			
	-					
	U AN					
	-					
		had 7.2%. P. 1568 discusses phospholipids and glyo or together).	coproteins as constituents of bovine m	ulk (which could be isolated alone		
		antibody to PAS-4 glycoprotein in the bovine milk f 61(9): 1568-74 P. 1571, left column, 4th paragraph, had 7.2%. P. 1568 discusses phospholipids and glycoprotein in the bovine milk f	at globule membrane. Biosci Biotech, glycoproteins WGP-88 contained a	nol Biochem. September 1997; 17.1% carbohydrate and PAS-4		
	-	HWANGBO, et al. Purification and characterization	on of novel whey glycoprotein WGP-	88 which binds to a monoclonal		
		CHU et al. Isolation and characterization of porcin column, first paragraph (lactoferrin "molecular ma	e milk lactoferrin. Am J Vet Res. Ju ss is estimated to be between 72,000-	ly 1993; 54(7):1154-9 P. 1154, left 85,000 daltons).		
		(i.e. dry eye treatment).				
Pharmacol Ther. April 1998; 14(2):99-107. A   inherently autoclavable), in a concentration o			t. Use of lactoferrin (glycoprotein ison 1% as a suggested opthlamic prep	platable from bovine milk whey, aration for corneal epithelial integrity		
INITIAL		FUJIHARA et al., Lactoferrin suppresses loss of co	rneal epithelial integrity in a rabbit s	hort-term dry eye model. J. Ocul		
*EXAMINER		OTHER DOCUMENTS (Including Author, Titl				
			Filing Date 03/30/04	Group Art Unit		
~		(Use several sheets if necessary)	EDWARD J. ELLIS, ET AL.			
INFORMATION DISCLOSURE CITATION			MTH-0003-P2 Applicant(s)	10/813,998		
<u>.</u>			Docket Number (Optional)	Application Number		

P09B/REV04

not considered. Include copy of this form with next communication to applicant.